Table 1.
Patient characteristics according to antibiotics group.
Fig 1.
AKI development probability graph according to the survival analysis and log-rank test.
Dotted red line marked indicates vancomycin monotherapy; continuous blue line indicates vancomycin plus piperacillin-tazobactam combination therapy; continuous black line represents vancomycin plus meropenem combination therapy; censored events were marked with crosses.
Table 2.
Comparison between acute kidney injury development according to treatment group.
Table 3.
Evaluation of clinical outcomes according to treatment group.
Table 4.
Effective factors for development of AKI.